Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.49 |
| ▸ | MAOA | P21397 | 7/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.49 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007646 | 1.00 | KDM1A (0.49) | KDM1AMAOARCOR1KDM1BESR2 | |
| SCHEMBL4169157 | 0.90 | CTSL (0.47) | ESR2P2RX7MMP8 | |
| SCHEMBL3664494 | 0.89 | KDM1A (0.55) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL2181843 | 0.88 | ESR2 (0.58) | ESR2 | |
| SCHEMBL4930098 | 0.85 | CTSL (0.47) | ESR2P2RX7MMP8 | |
| Iodide SCHEMBL4639203 | 0.85 | TMEM97 (0.44) | ESR2P2RX7MMP8 | |
| SCHEMBL3007628 | 0.84 | ESR2 (0.53) | ESR2 | |
| SCHEMBL3007625 | 0.84 | ESR2 (0.53) | ESR2 | |
| SCHEMBL17797697 | 0.83 | TMEM97 (0.55) | ESR2 | |
| SCHEMBL17797552 | 0.79 | TMEM97 (0.55) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | KDM1A 2025/4885MAOA 2584/4885RCOR1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.